Fintel reports that on January 22, 2025, RBC Capital downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) on January 21 and set a price target ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte (INCY – Research Report) on January 21 and set a price target of $70.00.

CF Industries Holdings, Inc. (CF) stock saw a decline, ending the day at $93.66 which represents a decrease of $-3.35 or -3.45% from the prior close of $97.01. The stock opened at $95.5 and touched a ...

RBC Capital Markets sized up Shopify Inc. (NYSE:SHOP) ahead of the company's Q4 earnings report due out in a few weeks. Analyst Paul Treiber said data from several third-party sources indicates ...

However, its 2025 costs and capital expenditure guidance exceeded analyst expectations as well as its own previous guidance. For full-year 2025, Hochschild expects capital expenditure between $197 ...

Wells Fargo CEO Charlie Scharf validates some of the optimism, telling analysts he feels "really great about our progress." ...

We recently compiled a list of the 7 Stocks That Could Surge From LA Wildfires Recovery Efforts. In this article, we are ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

We recently compiled a list of the 13 AI News and Ratings on Wall Street’s Radar. In this article, we are going to take a ...

The state of Colorado is moving forward with its plans to purchase Estes Park landmark The Stanley Hotel and fund a ...

The investment bank anticipates that the S&P 500 will end 2025 at 7,100 -- up roughly 20% from the current level. Take these ...